Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine

Jiao Guo

doi:10.1007/s11655-017-2811-3

Your Location：

Home >

Browse articles >

Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine

Updated：2021-08-27

- Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine
- Chinese Journal of Integrative Medicine Vol. 23, Issue 6, Pages: 403-409(2017)
- Affiliations：
  
  1. Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine
  2. Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine
  3. Key Unit of Modulating Liver in Treating Hyperlipidemia SACM, Institute of Traditional Chinese Medicine Research Institute, Guangdong Pharmaceutical University,Guangzhou,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81173626, 81530102, and 30973913)
- DOI：10.1007/s11655-017-2811-3
  CLC：
- Published：2017，
  
  Published Online：10 August 2017，
Scan for full text
Guo, J. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine., Chin. J. Integr. Med. 23, 403–409 (2017). https://doi.org/10.1007/s11655-017-2811-3

Jiao Guo. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine. [J]. Chinese Journal of Integrative Medicine 23(6):403-409(2017)
Guo, J. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine., Chin. J. Integr. Med. 23, 403–409 (2017). https://doi.org/10.1007/s11655-017-2811-3 DOI：

Jiao Guo. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine. [J]. Chinese Journal of Integrative Medicine 23(6):403-409(2017) DOI： 10.1007/s11655-017-2811-3.

摘要

Hyperlipidemia

type 2 diabetes mellitus

nonalcoholic fatty liver and many other metabolic disorder are frequently co-existing in patients. In addition

these diseases are closely related in pathophysiological settings. However

increasing of the disease incidence

lacking of comprehensive prevention and control measurements against the key pathology point concomitant occurrence with the pattern of the single disease

single target therapy

that is leading therapeutic strategy for these metabolic disorders in the setting of Western medicine (WM). On the basis of the combination of the advantages of integrated Chinese medicine (CM) and WM

with unified understanding of such diseases

the new concept of glucolipid metabolic disease (GLMD) is introduced. In this new concept

disorders in glucose and lipid metabolism are recognized as the key trigger and major driving force for the progress of GLMD. The key points of pathology included dysfunction of neuronal-endocrine-immune system

insulin resistance

oxidative stress

inflammation and intestinal flora imbalance. In the core pathogenic perspective of CM

it can be explained as "Gan (Liver) Shi Shu Xie" (dysfunction of Gan in metabolism and emotion regulation) that will lead to the occurence/production of endogenous dampness and phlegm

blood stasis and turbid. This leads to the new concept of "Liver-based regulatory system for metabolic homeostasis" to be introduced further. The comprehensive prevention and control strategy "Tiao Gan Qi Shu Hua Zhuo" (modulating Gan

trigging key metabolic system to resolve pathogenic factors such as phlegm retention and dampness). Its representative formula Fufang Zhenzhu Tiaozhi Capsule (复方贞术调脂胶囊) is innovated under such rationales. Comment for some commonly-used CM GLMD therapeutic drugs was presented. High-level evidence-based and epidemiological and mechanism studies should be carried out to further interpret and explain of the scientific connotation of GLMD.

Abstract

Hyperlipidemia

type 2 diabetes mellitus

nonalcoholic fatty liver and many other metabolic disorder are frequently co-existing in patients. In addition

these diseases are closely related in pathophysiological settings. However

increasing of the disease incidence

lacking of comprehensive prevention and control measurements against the key pathology point concomitant occurrence with the pattern of the single disease

single target therapy

with unified understanding of such diseases

the new concept of glucolipid metabolic disease (GLMD) is introduced. In this new concept

insulin resistance

oxidative stress

inflammation and intestinal flora imbalance. In the core pathogenic perspective of CM

it can be explained as "Gan (Liver) Shi Shu Xie" (dysfunction of Gan in metabolism and emotion regulation) that will lead to the occurence/production of endogenous dampness and phlegm

关键词

glucolipid metabolic diseaseliver-based regulatory system for metabolic homeostasisTiao Gan (Liver) Qi Shu Hua Zhuo (modulating Gantrigging key metabolic system to resolve pathogenic factors such as phlegm retention and dampness)Chinese Medicine

Keywords

references

World Health Organization. Global report on diabetes. Accessed September 10, 2016. Available at http://www.who.int/diabetes/publications/grd-2016/en/-28k

Chen WW, Gao YL, Liu LS, Zhu ML, Wang W, Wang YJ, et al. Summary of the Reports on Cardiovascular Disease in China (2015). Chin Circulat J (Chin) 2016;31:521–528.

Ji LN, Hu DY, Pan CY, Wen JP, Huo Y, Ma CS, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013;126:925.e11-22.

Li JH, Mi SQ, Li YC. The levels and distribution of the serum lipid in Chinese alduts 2010. Chin J Prevent Med (Chin) 2012;46:607–612.

Piao SH, Guo J, Hu ZP. Clinical research of Chinese medicine syndromes of hyperlipidemia inpatients. Chin J Integr Tradit West Med (Chin) 2012;3:1322–1325.

Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229–234.

Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901–2907.

Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553.

Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2005;28:2289–2304.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2005;112:2735–2752.

Mc Garry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7–18.

Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001;414:799–806.

Corkey BE. Banting lecture 2011: hyperinsulinemia: cause or consequence? Diabetes 2012;61:4–13.

Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012;15:635–645.

Levin BE, Magnan C, Dunn-Meynell A, Le Foll C. Metabolic sensing and the brain: who, what, where, and how? Endocrinology 2011;152:2552–2557.

Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature 2016;535:65–74.

Ye Y. Hyperlipidemia and phlegm turbid blood clot correlation: theory foundation and research basis. Lishizhen Med Mater Med Res (Chin) 2006;17:1561–1562.

Zhen AH. Traditional Chinese medicine clinical research progress of prevention and treatment of hyperlipidemia. Hunan Chin Med J (Chin) 2000;16:75–78.

Guo J, Piao SH, Bei WJ. Further discussion of the role of liver in the onset of hyperlipidemia. J New Chin Med (Chin) 2011;2:1–3.

Guo J, Piao SH. To explore the pathogenesis of traditional Chinese medicine from the younger age trend of hyperlipidemia incidence. Inform Tradit Chin Med (Chin) 2008;25:4–6.

Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 2013;153:747–758.

Liang Q, Zhong L, Zhang J, Wang Y, Bornstein SR, Triggle CR, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 2014;63:4064–4075.

Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012;26:312–324.

Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004;110:1492–1498.

Wang Y. Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2. Br J Pharmacol 2012;165:603–621.

Hoo RL, Lee IP, Zhou M, Wong JY, Hui X, Xu A, et al. Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice. J Hepatol 2013;58:358–364.

Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D, et al. Adipocyte fatty acidbinding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem 2010;285:10273–10280.

Guo J, Bei WJ, Hu YM, Tang CP, He W, Liu XB, et al. A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats. J Ethnopharmacol 2011;135:299–307.

Yao HX, Guo J, Tang CP, Yang CY, Chen YF, Chen YF, et al. Liver hypolipidemic protection of Compound Zhenzhu Tiaozhi Capsule on nonalcoholic fatty liver disease in rats and its mechanism. Chin Tradit Herb Drugs (Chin) 2011;10:2047–2077.

Hu XG, Wang M, Bei WJ, Han ZY, Guo J. The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome. J Translat Med 2014;12:47.

Tang FT, Guo J, He W, Wang LJ, Luo DS, Bei WJ. Effects of Fufang Zhenzhu Tiaozhi Prescription, a Chinese herbal preparation, on atherosclerosis in ApoE-/- mice and related mechanisms. Chin J Integr Med 2011.

Wang C, Liang XC. Clinical and experimental research progress on traditional Chinese medicine treatment of diabetes with hyperlipidemia. Chin J Clinic (Chin) 2015;43:26–30.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Liver-adipose tissue crosstalk: A key player in the pathogenesis of glucolipid metabolic disease

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Effect of Ermiao Recipe (二妙方) with medicinal guide Angelicae Pubescentis Radix on promoting the homing of bone marrow stem cells to treat cartilage damage in osteoarthritis rats

Related Author

No data

Related Institution

Guangdong Research Center of Metabolic Diseases of Integrated Western and Chinese Medicine, Guangdong Pharmaceutical University

Joint Laboratory between Guangdong and Hong Kong on Metabolic Disease, Guangdong Pharmaceutical University

State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong

Georg-August-Universität Göttingen, Göttingen

The Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics’ Ministry of Public Health

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰